Clinical manifestations in patients with ovarian clear cell carcinoma with or without co-existing endometriosis

Gynecological Endocrinology

Volumn 25, Issue 7, 2009, Pages 435-440

  Lim, Myong Cheol ^a,b   Lee, Dong Ock ^a   Kang, Sokbom ^a   Seo, Sang Soo ^a   Lee, Bo Yon ^b   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Clear cell adenocarcinoma; Endometriosis; Ovarian cancer; Symptoms

Indexed keywords

CA 125 ANTIGEN;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER REGISTRY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; KOREA; MEDICAL RECORD; OVARY CARCINOMA; PALPATION; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CA-125 ANTIGEN; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREVALENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 70350633009     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590902770131     Document Type: Article

References (34)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Chung HH, Hwang SY, Jung KW, Won YJ, Shin HR, Kim JW, Lee HPI. Ovarian cancer incidence and survival in Korea: 1993-2002. Int J Gynecol Cancer 2007;17:595-600.
3. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993;49:250-254.
4. Cha SH, Park H, Seong SJ, Kim TJ, Lim KT, Chung HW, Park IS, Shim JU, Park JT, Chun YK, et al. Clinicopathologic characteristics and survival rate of primary clear cell carcinoma of the ovary. Korean J Gynecol Oncol Colposc 2003;14: 140-150.
5. Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: A different entity? Oncologist 2006;11:1089-1094.
6. Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996;78:2157-2163.
7. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589.
8. Mostoufizadeh M, Scully RE. Malignant tumors arising in endometriosis. Clin Obstet Gynecol 1980;23:951-963.
9. Swiersz LM. Role of endometriosis in cancer and tumor development. Ann NY Acad Sci 2002;955:281-292; discussion 93-95, 396-406.
10. Somigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006;101:331-341.
11. Ness RB. Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. Am J Obstet Gynecol 2003;189: 280-294.
12. Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006;21:1237-1242.
13. Serov S, Scully R, Sobin L. International histologic classification of tumours, no.9. Histologic typing of ovarian tumours. Geneva: World Health Organization; 1973.
14. International Federation of Gynecology and Obstetrics (FIGO) Cancer Committee. Staging announcement. Gynecol Oncol 1986;25:383-385.
15. Russell P. The pathological assessment of ovarian neoplasms. I. Introduction to the common 'epithelial' tumours and analysis of benign 'epithelial' tumours. Pathology 1979;11: 5-26.
16. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996;60:238-244.
17. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-417.
18. Matsuura Y, Robertson G, Marsden DE, Kim SN, Gebski V, Hacker NF. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007; 104:406-410.
19. Aure JC, Hoeg K, Kolstad P. Carcinoma of the ovary and endometriosis. Acta Obstet Gynecol Scand 1971;50: 63-67.
20. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, Luchini L, Crosignani PG. Endometriosis and ovarian cancer. Am J Obstet Gynecol 1993;169:181-182.
21. Kurman RJ, Craig JM. Endometrioid and clear cell carcinoma of the ovary. Cancer 1972;29:1653-1664.
22. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, Kamura T, Nakano H. Ovarian endometriosis associated with ovarian carcinoma: A clinicopathological and immunohistochemical study. Gynecol Oncol 2000;77: 298-304.
23. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: Its close association with malignant epithelial tumours. Histopathology 1997;30:249-255.
24. Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obstet 1997;59:245-250.
25. Komiyama S, Aoki D, Tominaga E, Susumu N, Udagawa Y, Nozawa S. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: Clinicopathologic evaluation. Gynecol Oncol 1999;72:342-346.
26. Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS. Ovarian cancer: Can we make the clinical diagnosis earlier? Cancer 2005;104:1398-1407.
27. Cheng YM, Wang ST, Chou CY. Serum CA-125 in preoperative patients at high risk for endometriosis. Obstet Gynecol 2002;99:375-380.
28. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-408.
29. Yoo SC, Yoon JH, Lyu MO, Kim WY, Chang SJ, Chang KH, Ryu HS. Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer. J Gynecol Oncol 2008;19:169-172.
30. Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002;187:385-392.
31. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-346.
32. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA. Advanced stage clear-cell epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102:285-291.
33. Weideman M. Danazol linked to ovarian cancer. Lancet Oncol 2002;3:261.
34. Saylam K, Devreker F, Simon P, Fayt I, Noel JC. Ovarian clear cell carcinoma occurring in a young patient with endometriosis and long-term ovulation stimulations. Acta Obstet Gynecol Scand 2006;85:1506-1507.